Election 2014
SENSEX NIFTY
You are here : Moneycontrol > Mutual Funds > Sector - Pharma & Healthcare > UTI Mutual Fund > UTI Pharma & Healthcare Fund (G)

UTI Pharma & Healthcare Fund (G) SET SMS ALERT

61.110
0.41 (0.68%)
NAV as on Apr-17-2014
ranking by CRISIL

Not Ranked

This scheme is not ranked by CRISIL since it does not fulfill certain eligibility criteria of CRISIL

View Top ranked funds in other categories

Benchmark Index:
 
View Historic Graph From     To     

Returns (NAV as on Apr-17-2014)

Period Returns (%) Rank #
1 mth 1.8 3
3 mth 2.4 6
6 mth 10.4 6
1 year 27.1 6
2 year 20.9 3
3 year 15.7 3
5 year 26.4 3

# Moneycontrol Rank within 6 Sector - Pharma & Healthcare Schemes.

Absolute Returns (in %)

Year Qtr 1 Qtr 2 Qtr 3 Qtr 4 Annual
2014 0.9 - - - -
2013 -4.1 10.0 5.5 8.3 23.0
2012 6.9 2.3 8.0 4.9 25.0
2011 -7.8 6.1 -7.2 -0.7 -10.0
2010 11.8 8.9 1.4 9.9 37.4
2009 -1.3 18.2 25.1 -0.2 65.7

View where it stands within its peers

* Returns over 1 year are Annualised

Performance

Fund returns v/s Category average (Sector - Pharma & Healthcare)

* Returns over 1 year are Annualised
  1 mth (%) 3 mth (%) 6 mth (%) 1 yr (%) 2 yr (%) 3 yr (%) 5yr (%)
Fund Returns 1.8 2.4 10.4 27.1 20.9 15.7 26.4
Category avg 1.4 3.4 13.4 28.9 11.7 9.1 15.5
Difference of Fund returns and Category returns 0.4 -1.0 -3.0 -1.8 9.2 6.6 10.9
Best of category 1.9 4.1 18.4 30.3 27.6 22.3 33.6
Worst of category 0.6 2.4 10.4 27.1 20.9 15.7 26.4
Benchmark returns # 2.2 1.6 5.2 25.2 24.5 20.3 --
Difference of Fund returns and Benchmark returns -0.4 0.8 5.2 1.9 -3.6 -4.6 26.4
# Benchmark Index: CNX Pharma

Investment Info

Investment Objective

Investment will be made in stocks of companies engaged in manufacturing of Pharmaceuticals bulk drugs, formulations & OTC drugs, medical equipment and accessories, personal healthcare products and also companies owning/managing hospitals etc.

Scheme details

Fund Type Open-Ended
Investment Plan Growth
Launch date Jun 26, 1999
Benchmark CNX Pharma
Asset Size (Rs cr) 128.70 (Dec-31-2013)
Minimum Investment Rs.5000
Last Dividend N.A. View Dividend History
Bonus N.A.
Fund Manager Lalit Nambiar
View performance of schemes managed by the Fund Manager
Notes N.A

Load Details

Entry Load N.A
Exit Load 1.00%
Load Comments Exit Load 1% if redeemed within 1 Year from the date of allotment.

Contact Details

Regd. Office UTI Tower, Gn Block, Bandra-Kurla Complex, Bandra (E), Mumbai, 400051
Tel. No. 66786666
Fax No. 26524921
Email uti@giasbm01.vsnl.net.in
Website http://www.utimf.com

Peer Comparison

Sector - Pharma & Healthcare Crisil Rank Assets (Rs.cr)
3mth (%) 6mth (%) 1yr (%) 3yr (%) 5yr (%)
Reliance Pharma Fund (G) Not Ranked
703.28 3.4 17.9 28.7 16.8 33.6
SBI Pharma Fund (G) Not Ranked
130.15 4.0 11.2 29.4 22.3 32.8
UTI Pharma & Health (G) Not Ranked
128.70 2.4 10.4 27.1 15.7 26.4
Reliance Pharma Fund - Direct (G) Not Ranked
20.12 3.6 18.4 29.6 -- --
SBI Pharma Fund - Direct (G) Not Ranked
16.29 4.1 11.6 30.3 -- --
* Returns over 1 year are Annualised More »

Portfolio

Top Holdings (Mar 31, 14)

Equity Sector Value
(Rs cr)
Asset %
Sun Pharma Pharmaceuticals 30.54 21.36
Dr Reddys Labs Pharmaceuticals 21.92 15.33
Lupin Pharmaceuticals 13.20 9.23
Cipla Pharmaceuticals 12.95 9.06
Divis Labs Pharmaceuticals 7.56 5.29
Biocon Pharmaceuticals 5.25 3.67
Cadila Health Pharmaceuticals 4.68 3.27
Glenmark Pharmaceuticals 3.86 2.70
Wyeth Pharmaceuticals 3.53 2.47
Aurobindo Pharm Pharmaceuticals 3.13 2.19

Full Portfolio

Sector Allocation (Mar 31, 14)

Sector %

1-Year

HighLow

Pharmaceuticals 88.35 95.42 88.35

View All Sectors

Asset Allocation (%)(Mar 31, 14)

Equity 88.35
Others 0.00
Debt 0.09
Mutual Funds N.A
Money Market 0.00
Cash / Call 11.53

View All

Concentration

Holdings (%)
Top 5 60.27
Top 10 74.57
Sector (%)
Top 3 88.35

News & Videos

Messages & Community

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.